Eli Lilly has locked in a landmark $7 billion acquisition of Kelonia Therapeutics to pioneer a new class of cancer treatment that reprograms immune cells entirely inside the patient’s body.
The deal includes a $3.25 billion upfront payment, with up to $3.75 billion in future milestone payouts tied to clinical and commercial success.
Kelonia’s lead one-shot IV therapy, KLN-1010, has already delivered early proof-of-concept data for multiple myeloma, potentially bypassing the costly, time-intensive process of external cell engineering.
In a bold move to reshape the oncology landscape, Eli Lilly announced Monday its acquisition of biotech innovator Kelonia Therapeutics in a deal that could reach $7 billion, signaling a major pivot toward next-generation, in vivo cell therapy. Unlike conventional CAR-T approaches that require extracting a patient’s cells, modifying them in a lab over several weeks, and then reinfusing them, Kelonia’s proprietary in vivo gene placement system, branded iGPS,uses engineered lentiviral particles to transform a patient’s own T-cells directly inside the body. This off-the-shelf approach promises to slash manufacturing bottlenecks, reduce logistical burdens, and expand access to life-saving therapy for thousands of blood cancer patients who currently face long waiting lists or geographic barriers.
Under the terms of the agreement, Kelonia shareholders will receive $3.25 billion upfront, with an additional $3.75 billion tied to specific regulatory, clinical, and commercial milestones. The transaction, subject to customary approvals, is expected to close in the second half of 2026. This acquisition marks Lilly’s third major oncology bet in recent months, following its $7.8 billion pursuit of Centessa Pharmaceuticals and a $2.75 billion AI-driven drug discovery collaboration with Insilico Medicine. For Lilly, which has historically lacked a significant footprint in cell therapy, the deal provides an immediate entry into one of the most disruptive frontiers in immuno-oncology.
Kelonia’s lead candidate, KLN-1010, is a one-time intravenous therapy designed to generate anti-BCMA CAR-T cells internally, targeting multiple myeloma. Early clinical results, presented at the 2025 American Society of Hematology Annual Meeting, showed strong tolerability and initial proof-of-concept for the platform, with the therapy now in Phase I trials. According to Lilly’s oncology leadership, the ability to deliver rapid, durable responses in a simpler, more scalable format could fundamentally redefine treatment paradigms. Kelonia CEO Kevin Friedman emphasized that combining Lilly’s commercial muscle with Kelonia’s iGPS platform could extend cell therapy’s reach far beyond hematologic malignancies into solid tumors and other serious diseases. With this high-stakes acquisition, Lilly is not just buying a drug candidate, it is placing a $7 billion wager on the future of in vivo genetic medicine.
